多药耐药蛋白MRP1的基质识别的结构基础
Zachary Lee Johnson1, Jue Chen1
1Laboratory of Membrane Biology and Biophysics, The Rockefeller University and the Howard Hughes Medical Institute, 1230 York Avenue, New York, NY 10065, USA.
Cell
|February 28, 2017
概括
多种药物耐药性相关蛋白1 (MRP1) 载体
科学领域:
- 生物化学
- 分子生物学
- 结构生物学
背景情况:
- 多种药物耐药性蛋白1 (MRP1) 是一种ATP结合盒 (ABC) 载体.
- MRP1与抗癌药物耐药性,药物处置以及炎症和激素分泌等生理过程有关.
研究的目的:
- 确定牛MRP1在apo和基质结合状态中的分子结构.
- 阐明MRP1中基质识别和形状变化的机制.
主要方法:
- 使用电子冷显微镜 (cryo-EM) 来解析MRP1的结构.
- 获得了高分辨率结构的apo MRP1 (3.5 Å) 和MRP1复合的leukotriene C4 (3.3 Å).
主要成果:
- 这些结构显示MRP1中单一的双重结合点能够容纳多种基质.
- 叶氨酸C4结合会诱导显著的构造变化,从而为ATP水解做准备.
- 与P-糖蛋白的结构比较凸显了与多药性耐药性相关的保存和独特特征.
结论:
- MRP1的双重结合部位解释了其广泛的基质特异性.
- 基质诱导的形状变化对MRP1的传输机制至关重要.
- 了解MRP1的结构功能关系有助于深入了解多种药物耐药性和化疗疗效.
相关概念视频
Directing Proteins to the Rough Endoplasmic Reticulum
18.1K
The organelle-specific signaling sequences direct proteins synthesized in the cytosol to their final destination like ER, mitochondria, peroxisomes, etc. Some of the proteins directed to ER are then trafficked via vesicles to other organelles within the cell or the extracellular environment through the Golgi complex. For example, the rough ER synthesizes soluble proteins for transportation to the lysosomes or secretion out of the cell. It can also synthesize transmembrane proteins that can...
18.1K
Insertion of Multi-pass Transmembrane Proteins in the RER
19.1K
The rough ER membrane synthesizes, assembles, and embeds transmembrane proteins in diverse topologies. These proteins function as transporters or channels and can remain in the ER membrane or are sent to the Golgi complex, lysosome, and cell membrane.
The multipass transmembrane proteins are the type IV integral membrane proteins with multiple topogenic sequences determining their spatial arrangement in the ER membrane. Nearly all multipass proteins lack a cleavable signal sequence and use...
The multipass transmembrane proteins are the type IV integral membrane proteins with multiple topogenic sequences determining their spatial arrangement in the ER membrane. Nearly all multipass proteins lack a cleavable signal sequence and use...
19.1K
Carrier-Mediated Transport
1.4K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.4K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
83
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
83
The Significance of Membrane Transport
43.3K
The transport of solutes across the cell membrane is essential for metabolic processes, like maintaining cell size and volume, generating the action potential, exchanging nutrients and gases, etc. Membrane transport can be either passive or active. It can be simple diffusion, facilitated, or mediated transport aided by transport proteins such as transporters and channels.
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
Transporters facilitate either an active or passive movement of solutes. They can allow a single-molecule transport down its...
43.3K
Export of Misfolded Proteins out of the ER
5.4K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.4K


